ARTICLE | Product Development
Early-stage venture funding dries up for U.S. cell and gene therapy biotechs
As seed and series A funding falls off a cliff for U.S. cell and gene therapy start-ups, China becomes a bright spot
Negative sentiment around the commercial prospects of cell and gene therapies has begun to affect the earliest stages of technology development, with fewer new companies attracting venture funding. But within that shrinking pool of start-ups, a shift is emerging toward innovations aimed at lowering commercial barriers and potentially reversing sentiment.
A BioCentury analysis of seed and series A financings from 2020 to 2025 shows a marked decline in the number of cell and gene therapy start-ups receiving early venture backing, both in absolute terms and relative to the broader biotech landscape...